Wells Fargo
DERM icon

Wells Fargo’s Journey Medical DERM Stock Holding History

Wells Fargo’s Portfolio DERM Stock Details DERM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-7,501
Closed -$35.2K – 7369
2026
Q1 		$35.2K Sell
7,501
-8,247
-52% -$64K ﹤0.01% 5569
2025
Q4 		$121K Buy
15,748
+8,215
+109% +$64.4K ﹤0.01% 5310
2025
Q3 		$53.6K Buy
7,533
+1,260
+20% +$9.14K ﹤0.01% 5531
2025
Q2 		$45K Buy
+6,273
New +$43.4K ﹤0.01% 5544
2024
Q2 		– Sell
-61
Closed -$224 – 7027
2024
Q1 		$224 Buy
61
+1
+2% +$4 ﹤0.01% 6468
2023
Q4 		$346 Buy
60
+4
+7% +$18 ﹤0.01% 6467
2023
Q3 		$153 Buy
56
+8
+17% +$18 ﹤0.01% 6645
2023
Q2 		$76 Buy
48
+2
+4% +$3 ﹤0.01% 6937
2023
Q1 		$72 Buy
46
+2
+5% +$4 ﹤0.01% 7014
2022
Q4 		$84 Buy
44
+1
+2% +$2 ﹤0.01% 6838
2022
Q3 		$0 Buy
43
+14
+48% +$48 ﹤0.01% 6766
2022
Q2 		$0 Buy
29
+4
+16% +$16 ﹤0.01% 6909
2022
Q1 		$0 Buy
+25
New +$125 ﹤0.01% 7178

Other funds holding DERM

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAIM
Punch & Associates Investment Management Edina, Minnesota $2.02B AUM 40.6% 1-Year Est. Return
PFCS
Pale Fire Capital SE Prague, Czech Republic $1.41B AUM 25.22% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
SF
Summit Financial Parsippany, New Jersey $9.12B AUM 27.44% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
DC
Diametric Capital Boston, Massachusetts $948M AUM 47.49% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Wells Fargo's DERM Position: Q2 2026 in Review

Wells Fargo sold out of Journey Medical (DERM) in Q2 2026, closing a stake of 7,501 shares — an estimated $35.2K sold.

Wells Fargo first reported a position in DERM in Q1 2022 and held it in 13 quarters. The position peaked at $121K in Q4 2025. 71 funds tracked by Wall St. Rank hold DERM as of Q2 2026.

  • Wells Fargo reported no remaining Journey Medical position as of Q2 2026 after selling out during the quarter.
  • Wells Fargo sold 7,501 Journey Medical shares in Q2 2026, an estimated $35.2K.
  • Wells Fargo first reported a position in Journey Medical in Q1 2022 and held it in 13 quarters.
  • Wells Fargo's Journey Medical position peaked at $121K in Q4 2025.
  • 71 funds tracked by Wall St. Rank held Journey Medical as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.